Tumors and Tumor-Like Lesions of the Hepatobiliary Tract 2016

DOI: 10.1007/978-3-319-26587-2_141-1

|View full text |Cite

|

Sign up to set email alerts

|

Tumor-like Lesions: Fibrosclerotic Lesions of the Hepatobiliary Tract

Arthur Zimmermann¹

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Malignant Vascular Tumours1

Discussion1

Pathogenesis Of O Viverrini Induced Chola...1

Introduction1

Citation Types

Supporting

0

Mentioning

4

Contrasting

0

Year Published

2021

2021

2023

2023

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(4 citation statements)

References 192 publications

Supporting

0

Mentioning

4

Contrasting

0

Order By: Relevance

“…The consideration of hemangioendothelioma type 2 as a low grade angiosarcoma also seems to be supported by the Zimmerman’s description of an overlapping entity between the former type 2 and a distinct form of an infantile hepatic angiosarcoma ( 63 , 64 ).…”

Section: Malignant Vascular Tumoursmentioning

confidence: 86%

The role of liver transplantation in the care of primary hepatic vascular tumours in children

¹

,

²

,

³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Liver transplantation (LT) is the standard of care for many liver conditions, such as end-stage liver diseases, inherited metabolic disorders, and primary liver malignancies. In the latter group, indications of LT for hepatoblastoma and hepatocellular carcinoma evolved and are currently available for many non-resectable cases. However, selection criteria apply, as the absence of active metastases. Evidence of good long-term outcomes has validated the LT approach for managing these malignancies in the context of specialist and multidisciplinary approach. Nevertheless, LT’s role in treating primary vascular tumours of the liver in children, both benign and malignant, remains somewhat controversial. The rarity of the different diseases and the heterogeneity of pathological definitions contribute to the controversy and make evaluating the benefit/risk ratio and outcomes quite difficult. In this narrative review, we give an overview of primary vascular tumours of the liver in children, the possible indications and the outcomes of LT.

“…The consideration of hemangioendothelioma type 2 as a low grade angiosarcoma also seems to be supported by the Zimmerman’s description of an overlapping entity between the former type 2 and a distinct form of an infantile hepatic angiosarcoma ( 63 , 64 ).…”

Section: Malignant Vascular Tumoursmentioning

confidence: 86%

The role of liver transplantation in the care of primary hepatic vascular tumours in children

¹

,

²

,

³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Liver transplantation (LT) is the standard of care for many liver conditions, such as end-stage liver diseases, inherited metabolic disorders, and primary liver malignancies. In the latter group, indications of LT for hepatoblastoma and hepatocellular carcinoma evolved and are currently available for many non-resectable cases. However, selection criteria apply, as the absence of active metastases. Evidence of good long-term outcomes has validated the LT approach for managing these malignancies in the context of specialist and multidisciplinary approach. Nevertheless, LT’s role in treating primary vascular tumours of the liver in children, both benign and malignant, remains somewhat controversial. The rarity of the different diseases and the heterogeneity of pathological definitions contribute to the controversy and make evaluating the benefit/risk ratio and outcomes quite difficult. In this narrative review, we give an overview of primary vascular tumours of the liver in children, the possible indications and the outcomes of LT.

“…Such heterogeneity of clinical findings, imaging characteristics, and histopathologic features can often obscure the precise diagnosis in these patients. [ 4 ] For example, cHCC/CCA described in case 1 displays phenotypic features suggestive of both hepatic and biliary differentiation, making the preoperative diagnosis exceptionally challenging. This is true of the other tumor subtypes as well.…”

Section: Discussionmentioning

confidence: 99%

“…Cholangiocarcinoma, the next most common primary liver cancer, is also associated with a high mortality that is generally attributed to advanced stage disease at the time of diagnosis. Several prognostic factors for liver cancers have been proposed, including tumor size, vascular invasion, elevated serum tumor markers (e.g., alpha-fetoprotein (AFP) and carbohydrate antigen 19-9 (CA 19-9)), resection margin status, and tumor histology [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Rare Histological Variants of Liver Cancer and Their Management: A Single-Institution Experience

¹

,

²

,

³

et al. 2021

Case Reports in Hepatology

View full text Add to dashboard Cite

Primary liver malignancies, including hepatocellular carcinoma (HCC) and cholangiocarcinoma, are a major cause of cancer-related morbidity and mortality worldwide. There are several histologically and biologically distinct subtypes of liver cancer that have previously been reported. However, literature regarding the nonsurgical management of these patients upon disease recurrence remains limited. These variants include combined HCC-cholangiocarcinoma (cHCC-CC), Epstein–Barr virus- (EBV-) associated carcinoma, undifferentiated carcinoma, and clear cell or thyroid-like variants of HCC. Here, we aim to highlight the pathologic features, clinical course, and outcomes of five patients with these unusual hepatic tumors and explain the rationale behind the choice of their systemic therapies upon disease recurrence. All patients underwent surgical resection as the standard of care for localized disease, and upon relapse, they were treated with either chemotherapy, targeted therapy, immunotherapy, or active surveillance based on the clinical context and tumor histology. These rare variants are important to recognize as they have prognostic and therapeutic implications, and there are currently insufficient data in the literature to guide further therapy.

“…The mechanism of O. viverrini induced CCA is uncertain, but chronic inflammation is thought to play a role as results from the flat worm infecting the host’s biliary tract. ( Chaiyadet et al ., 2015 ; Zimmermann, 2019 ). The most frequent cause of CCA is malignant transformation of cholangiocyte cells, while it is also possible for peribiliary gland epithelial cells and/or biliary stem cells to evolve into cancer.…”

Section: Pathogenesis Of O Viverrini Induced Chola...mentioning

confidence: 99%

Fish and Food-Fatale: Food-borne Trematode Opisthorchis viverrini and Cholangiocarcinoma

Tan,

Machrumnizar

2023

Helminthologia

View full text Add to dashboard Cite

Summary Neglected Tropical Diseases (NTDs) are a group of communicable diseases with a long history with human beings. NTDs are the proxy of poverty since they affect those in low-income and extreme-poverty populations, as those populations lack access to proper health care, clean water, sanitary conditions, and hygiene. NTDs create losses for a nation that come from the health and the economic sectors as well since the costs of diagnosis, prevention, and treatment strain the national purse strings. One of the 20 different forms of NTDs on the list is food-borne trematodes, comprises of Fasciola, Paragonimus, Clonorchis, and Opisthorchis. Currently, it is estimated that food-borne trematodes can cause a devastating effect on mortality and morbidity. All of them are zoonotic, as humans become infected by ingestion of a second intermediate host, such as freshwater snails, fish, or water vegetables. Opisthorchis viverrini, one of the food-borne trematodes that can be found mostly in South East Asia regions, especially in the Mekong basin, is regarded as a group 1 carcinogen leading to cholangiocarcinoma (CCA). This study aims to present the updated review of Opisthorchis viverrini and CCA.

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Product

Browser Extension Assistant by scite Citation Statement Search Reference Check Visualizations Dashboards Explore Journals Explore Organizations Explore Funders Embedding Badge Embedding Citation Search Pricing

Resources

Blog Help & FAQ Accessibility Statement API Terms For Universities & Governments For Researchers For Publishers For Corporate, Pharma & Enterprise Author Marketing Become an Affiliate Get an organization trial or quote scite Data & Services

About

News & Press Careers Read our Paper Coverage

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Copyright © 2024 scite LLC. All rights reserved.

Made with 💙 for researchers

Part of the Research Solutions Family.